Drug search by name

Mavyret and Liver dysfunction

Result of checking the interaction of drug Mavyret and disease Liver dysfunction for safety when used together.

Check result:

Mavyret <> Liver dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of the co-formulated presentation of glecaprevir and pibrentasvir is not recommended in patients with moderate hepatic impairment (Child-Pugh B); and is contraindicated in patients with severe hepatic impairment (Child-Pugh C) due to higher exposures of glecaprevir and pibrentasvir. No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh A). In addition, its use is associated with hepatitis B reactivation, some cases have resulted in fulminant hepatitis, hepatic failure, and death, in HCV/HBV coinfected patients. Screening for current or prior viral hepatitis B/C infection should be performed per published guidelines before starting therapy with this agent. It is recommended to monitor patients coinfected with HCV/HBV for hepatitis flare or HBV reactivation during and after HCV therapy. Prescribers should exercise caution when treating patients previously infected with HBV/HCV. It is recommended to initiate appropriate patient management for HBV infection as clinically indicated.

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand Name: Mavyret

Synonyms: n.a.

What is Mavyret?